• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Myomo Announces First Private Payer Contracts for MyoPro In-network Coverage

    10/31/24 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care
    Get the next $MYO alert in real time by email

    Blue Cross Blue Shield of Massachusetts and Paradigm together serve 3 million covered lives

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces it has entered into the first contracts that will allow MyoPro to be provided to patients covered by private insurance on an in-network basis.

    These new contracts are with Blue Cross Blue Shield of Massachusetts, a leading commercial and Medicare Advantage insurer, and Paradigm, a leading specialty care management organization serving workers' compensation and healthcare payers. Paradigm's contract represents its commitment to assessing and evaluating appropriateness of medical innovations like the MyoPro for injured workers. Together, these organizations cover approximately 3 million lives.

    "Entry into these first in-network payer contracts represents a key milestone for Myomo and an expansion of coverage for patients suffering from neurological disorders and upper-limb paralysis," said Harry Kovelman, M.D., Myomo's chief medical officer. "We are continuing our outreach to other private payers and I'm encouraged by the reception we've received to date. With coverage for the MyoPro now provided by Medicare Part B, and commercial insurers and specialty care management organizations starting to enter into contracts with us, we believe the MyoPro is on its way toward becoming the standard of care for those suffering with permanent upper extremity impairment who want to regain their ability to perform activities of daily living."

    About Blue Cross Blue Shield of Massachusetts

    Blue Cross Blue Shield of Massachusetts (bluecrossma.org) is a community-focused, tax-paying, not-for-profit health plan headquartered in Boston. It is committed to showing up for everyone like they're the only one and guiding its members to the exceptional health care they deserve – affordably, equitably and seamlessly. In keeping with its commitment, it is rated among the nation's best health plans for member satisfaction and quality.

    About Paradigm

    Paradigm is an accountable specialty care management organization focused on improving the lives of people with complex injuries and diagnoses. The company has been a pioneer in value-based care since 1991 and has an exceptional track record of generating the very best outcomes for patients, payers and providers. Deep clinical expertise is the foundation for every part of Paradigm's business: risk-based clinical solutions, case management, specialty networks, home health, shared decision support and payment integrity programs.

    About Myomo

    Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient's own EMG signals through non-invasive sensors on the arm, can restore an individual's ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241031865271/en/

    Get the next $MYO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • What significant development has Myomo achieved with Blue Cross Blue Shield of Massachusetts and Paradigm?

      The new contracts with Blue Cross Blue Shield of Massachusetts and Paradigm will allow MyoPro to be provided on an in-network basis for patients covered by private insurance.

    • What does the announcement indicate about the future of Myomo’s MyoPro technology for patients?

      The entry into these contracts represents a key milestone in expanding coverage for patients with neurological disorders and upper-limb paralysis, aiming to make MyoPro a standard of care for those with permanent upper extremity impairment.

    • What is the function of Myomo's MyoPro device?

      MyoPro is a powered upper-limb orthosis that restores function to weakened or paralyzed arms, designed for patients suffering from conditions like stroke, traumatic brain injury, or neuromuscular diseases.

    • What are the key characteristics of Blue Cross Blue Shield of Massachusetts and Paradigm, the companies partnering with Myomo?

      Blue Cross Blue Shield of Massachusetts is a not-for-profit health plan dedicated to providing quality health care and ensuring member satisfaction, while Paradigm specializes in specialty care management, focusing on individuals with complex injuries.

    • How does Myomo plan to expand its coverage and market presence moving forward?

      With Medicare Part B coverage now provided for MyoPro and interest from other payers, Myomo is optimistic about the future expansion of its market presence and the adoption of its technology.

    Recent Analyst Ratings for
    $MYO

    DatePrice TargetRatingAnalyst
    7/31/2024$7.00Buy
    Craig Hallum
    5/20/2024$7.00Buy
    Lake Street
    12/15/2023$6.50Buy
    H.C. Wainwright
    More analyst ratings

    $MYO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Myomo Inc.

      SC 13G/A - MYOMO, INC. (0001369290) (Subject)

      10/18/24 2:21:35 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Myomo Inc.

      SC 13G/A - MYOMO, INC. (0001369290) (Subject)

      7/12/24 10:35:49 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Myomo Inc.

      SC 13G/A - MYOMO, INC. (0001369290) (Subject)

      7/11/24 6:02:07 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Leadership Updates

    Live Leadership Updates

    See more
    • Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

      2/3/25 4:00:00 PM ET
      $INGN
      $MDT
      $MYO
      Industrial Specialties
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Myomo Appoints Heather Getz to its Board of Directors

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic plannin

      3/28/24 4:05:00 PM ET
      $BFLY
      $MYO
      Medical Electronics
      Health Care
      Industrial Specialties
    • Myomo Appoints Yitzchak Jacobovitz to its Board of Directors

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Jacobovitz, 47, is currently a partner and lead healthcare analyst at AIGH Capital Management and affiliates ("AIGH"), where he has significantly grown AIGH's healthcare footprint since joining in 2014. Prior to AIGH, Mr. Jacobovitz was a managing director at Capstone, a policy research

      1/30/23 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Myomo Inc.

      10-Q - MYOMO, INC. (0001369290) (Filer)

      5/7/25 4:15:23 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MYOMO, INC. (0001369290) (Filer)

      5/7/25 4:10:10 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • SEC Form DEFA14A filed by Myomo Inc.

      DEFA14A - MYOMO, INC. (0001369290) (Filer)

      4/25/25 8:35:25 AM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MYO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: Chief Commercial Officer Mitchell Micah sold $247,565 worth of shares (48,000 units at $5.16), decreasing direct ownership by 25% to 140,269 units (SEC Form 4)

      4/A - MYOMO, INC. (0001369290) (Issuer)

      3/21/25 4:15:53 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Director Kirk Thomas F bought $37,000 worth of shares (7,400 units at $5.00), increasing direct ownership by 3% to 255,933 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      3/14/25 9:00:08 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Amendment: Chief Commercial Officer Mitchell Micah sold $247,565 worth of shares (48,000 units at $5.16), decreasing direct ownership by 25% to 140,572 units (SEC Form 4)

      4/A - MYOMO, INC. (0001369290) (Issuer)

      3/14/25 5:45:37 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Craig Hallum initiated coverage on Myomo with a new price target

      Craig Hallum initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

      7/31/24 7:20:07 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Lake Street initiated coverage on Myomo with a new price target

      Lake Street initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

      5/20/24 9:00:38 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • H.C. Wainwright initiated coverage on Myomo with a new price target

      H.C. Wainwright initiated coverage of Myomo with a rating of Buy and set a new price target of $6.50

      12/15/23 8:26:14 AM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Myomo Reports First Quarter 2025 Financial and Operating Results

      Revenue of $9.8 million Record 700 patients added to the pipeline More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2025. Financial and operating highlights for the first quarter of 2025 include the following (all comparisons are with the first quarter of 2024 unless otherwise indicated): Revenue was $9.8 million, up 162%; Revenu

      5/7/25 5:11:00 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo to Host Investor & Analyst Day Event on June 18, 2025

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces the Company will be hosting its first-ever Investor & Analyst Day event on Wednesday, June 18, 2025. The event will take place at Myomo's new corporate headquarters and manufacturing facility in Burlington, Mass., and will offer an in-depth look at the Company's latest innovations, strategic plans and growth initiatives to empower individuals with neuromuscular disorders through cutting-edge wearable medical robotics. Institutional investors, shareholders and analysts are invited to reg

      5/1/25 8:30:00 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo to Report First Quarter 2025 Financial Results on May 7

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2025 on May 7, 2025. The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the cal

      4/30/25 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kirk Thomas F bought $37,000 worth of shares (7,400 units at $5.00), increasing direct ownership by 3% to 255,933 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      3/14/25 9:00:08 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Kirk Thomas F bought $175,000 worth of shares (50,000 units at $3.50), increasing direct ownership by 27% to 236,499 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      5/31/24 5:43:26 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Kirk Thomas F bought $175,000 worth of shares (50,000 units at $3.50), increasing direct ownership by 37% to 186,499 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      3/18/24 7:48:52 AM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Financials

    Live finance-specific insights

    See more
    • Myomo Reports First Quarter 2025 Financial and Operating Results

      Revenue of $9.8 million Record 700 patients added to the pipeline More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2025. Financial and operating highlights for the first quarter of 2025 include the following (all comparisons are with the first quarter of 2024 unless otherwise indicated): Revenue was $9.8 million, up 162%; Revenu

      5/7/25 5:11:00 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo to Report First Quarter 2025 Financial Results on May 7

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2025 on May 7, 2025. The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the cal

      4/30/25 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo's Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million

      Generated first-ever positive quarterly cash flow from operations Received a record 233 MyoPro® authorizations and orders with 657 additions to the pipeline Introduces 2025 revenue guidance of $50 million to $53 million Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2024. Financial and operating highlights for the fourth quarter of 2024 include the following (all comparisons are with the fourth quarter of

      3/10/25 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care